Four years of daily supplementation with vitamin D3 (2000 IU) and marine omega-3 fatty acids (1 g) produced no statistically significant reduction in four plasma Alzheimer's disease biomarkers — NT1 tau fragment, amyloid beta 40:42 ratio, neurofilament-light (NfL), and GFAP — in 929 adults averaging age 65 from the well-designed VITAL randomized controlled trial. Intriguing subgroup signals emerged: Black participants showed a 16.2% reduction in NfL with vitamin D3 and a 12.4% reduction in GFAP with omega-3s, but neither finding survived correction for multiple comparisons.
This null result carries significant weight precisely because it comes from a large, placebo-controlled, 2×2 factorial RCT — the gold standard design — rather than an observational study. The VITAL trial has already delivered important negative or modest results across cardiovascular and cancer endpoints, and this dementia-biomarker analysis continues that sobering pattern. Many adults take these supplements partly hoping to protect cognitive health; this evidence offers little support for that rationale at standard supplementation doses.
The subgroup findings in Black participants are biologically plausible — vitamin D deficiency is more prevalent in darker-skinned populations — but the authors correctly flag these as hypothesis-generating only, uncorrected for multiple testing. The modest sample of Black participants (n≈76) further limits interpretation. Overall, this is confirmatory evidence that broad-spectrum supplementation at these doses is unlikely to meaningfully shift dementia-related biology in the general aging population without targeted selection by baseline deficiency status or genetic risk.